Pharma

Your Article Summary

See Latest Articles

Medtronics Resolute Drug-Eluting Stent Maintains Strong, Sustained Efficacy and Safety in Long-Term Follow-Up
Medtronic, 09/22/09

The single–arm RESOLUTE trial demonstrates a low, 1.6 percent cumulative rate of target lesion revascularization (TLR) – or repeat procedures to treat the previously stented portion of the vessel – with no new TLRs between two and three years of follow–up. Cumulative rates of other clinical events remained low as well, with no new myocardial infarctions or cardiac deaths after two years.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Autologous blood therapy for common cold—A randomized, double-blind, placebo-controlled trial
Complementary Therapies in Medicine, 12/08/09

Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial
Archives of Drug Information, 12/08/09

Cytokinetics Presents Non-Clinical Data Relating To CK-2017357 At The 5th Cachexia Conference
Cytokinetics, 12/08/09

 See all of Drug Trials